Table 5.
Incremental cost-effectiveness ratio results of studies that used other forms of glucosamine–sensitivity analyses
| At 2 months | At 3 months | At 6 months | |
|---|---|---|---|
| QALY change other glucosamine | 0.0004075 | 0.00056492 | 0.00311919 |
| QALY change placebo | 0.00080951 | 0.00140589 | 0.00595049 |
| Median cost other glucosamine | 33 | 59.4 | 118.8 |
| Median ICER | Placebo better | Placebo better | Placebo better |
| Lowest cost other glucosamine | 27 | 40.5 | 81 |
| Lowest ICER | Placebo better | Placebo better | Placebo better |
| Highest cost other glucosamine | 39.6 | 59.4 | 118.8 |
| Highest ICER | Placebo better | Placebo better | Placebo better |